Skip to main content
SpringerLink
Log in

Pharmacokinetics of Etoposide after Oral and Intravenous Administration in Patients with Gastric Carcinoma

  • Clinical Pharmacokinetics
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Summary

The effects of the primary tumour in situ or of gastrectomy on the bioavailability and other pharmacokinetic parameters of etoposide, after oral administration of commercially available etoposide (Vepesid®, Bristol-Myers Squibb) capsules, were studied in 8 patients with histologically proven gastric carcinoma. The dose of etoposide was 50mg. The oral bioavailability was found to be 56 ± 14%, which was similar to values reported in other studies in patients without malignancies of the gastrointestinal tract. After intravenous and oral administration, the apparent volumes of distribution were 21.5 ± 10.4 and 27.7 ± 11.1 L/m2, respectively, the mean residence times were 9.0 ± 2.6 and 10.2 ± 2.7 hours, respectively, and the elimination half-lives were 11.8 ± 5.9 and 7.8 ± 1.7 hours, respectively. These pharmacokinetic parameters were not significantly different after intravenous and oral administration. The plasma clearance of etoposide was 21.6 ± 3.2 ml/min/m2. The bioavailability of etoposide was not significantly altered (p > 0.05) by reversing the sequence of administration, nor were the apparent volume of distribution, the mean residence time or the terminal half-life of etoposide in plasma. Although the number of patients was small, it can be concluded that the pharmacokinetic parameters of etoposide are not altered in the presence of gastric cancer or gastrectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Slevin ML. Low-dose oral etoposide: A new role for an old drug? [editorial]. J Clin Oncol 1990; 8: 1607–9

    PubMed  CAS  Google Scholar 

  2. Slevin ML, Clark PI, Joel SP, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989; 7: 1333–40

    PubMed  CAS  Google Scholar 

  3. Clark PI, Slevin ML. The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 1987; 12: 223–52

    Article  PubMed  CAS  Google Scholar 

  4. Thompson DS, Hainsworth JD, Hande KR, et al. Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol 1993; 11: 1322–8

    PubMed  CAS  Google Scholar 

  5. Clark PI, Joel SP, Slevin ML. A pharmacokinetic hypothesis for the clinical efficacy of etoposide in small cell lung cancer. Proc Am Assoc Clin Oncol 1989; 8: 66

    Google Scholar 

  6. Slevin ML, Joel SP. Prolonged oral etoposide in small cell lung cancer [editorial]. Ann Oncol 1993; 4: 529–32

    PubMed  CAS  Google Scholar 

  7. Desoize B, Woirin V, Legros M, et al. Reduced oral etoposide bioavailability in patients with advanced cancer of the head and neck. J Natl Cancer Inst 1992; 84: 348–50

    Article  PubMed  CAS  Google Scholar 

  8. D’Incalci M, Farina P, Sessa C, et al. Pharmacokinetics of VP 16-213 given by different administration methods. Cancer Chemother Pharmacol 1982; 7: 141–5

    PubMed  Google Scholar 

  9. Joel SP, Dolega-Ossowksi E, Jones K, et al. The bioavailability of oral etoposide during prolonged administration and development of a limited sampling strategy for the estimation of AUC after an oral dose. Proc Am Assoc Cancer Res 1991; 32: 178

    Google Scholar 

  10. Taal BG, Teller FGM, Ten Bokkel-Huinink WW, et al. Etoposide, leucovorin, 5-fluorouracil, (ELF) combination chemotherapy for advanced gastric cancer: Experience with two treatment schedules incorporating intravenous or oral etoposide. Ann Oncol 1994; 5: 90–2

    PubMed  CAS  Google Scholar 

  11. Proost JH, Meijer DKF. MWPHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Computers Biol Med 1992; 22: 155–63

    Article  CAS  Google Scholar 

  12. Gibaldi M, Perrier D. Pharmacokinetics (revised and expanded). 2nd ed. New York: Marcel Dekker, Inc., 1982: 45–199

    Google Scholar 

  13. Powers JD. Statistical considerations in pharmacokinetic study design. Clin Pharmacokinet 1993; 24: 380–7

    Article  PubMed  CAS  Google Scholar 

  14. Sinkule JA, Evans WE. High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection. J Pharm Sci 1984; 73: 164–86

    Article  PubMed  CAS  Google Scholar 

  15. Armbrecht U, Lundell L, Lindstedt G, et al. Causes of malabsorption after total gastrectomy with Roux-en-Y reconstruction. Acta Chir Scand 1988; 154: 37–41

    PubMed  CAS  Google Scholar 

  16. Walther B, Clementsson C, Vallgren S, et al. Fat malabsorption in patients before and after total gastrectomy, studies by the triolein breath test. Scand J Gastroenterol 1989; 24: 309–14

    Article  PubMed  CAS  Google Scholar 

  17. Rieu PNMA, Jansen JBMJ, Joosten HJM, et al. Effect of gastrectomy with either Roux-en-Y or Billroth II anastomosis on small-intestinal function. Scand J Gastroenterol 1990; 25: 185–92

    Article  PubMed  CAS  Google Scholar 

  18. Yamamoto Y, Amano T, Fujimoto Y, et al. The effect of gastrectomy on serum 5-FU concentrations of patients administered UFT per os [in Japanese with English abstract]. Jpn J Cancer Clin 1987; 33: 377–81

    CAS  Google Scholar 

  19. Maehara Y, Takeuchi H, Oshiro T, et al. Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination. Cancer Chemother Pharmacol 1994; 33: 445–9

    Article  PubMed  CAS  Google Scholar 

  20. Cavalli F, Zucchetti M, Gentili D, et al. Phase I and clinical pharmacological evaluation of daily oral etoposide (VP16). Proc ASCO 1992; 11: 109

    Google Scholar 

  21. Hande KR, Krozely MG, Greco FA, et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993; 11: 374–7

    PubMed  CAS  Google Scholar 

  22. Marzola M, Zucchetti M, Colombo N, et al. Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol 1993; 4: 517–9

    PubMed  CAS  Google Scholar 

  23. Cunningham D, McTaggert L, Soukop M, et al. Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Med Oncol Tumor Pharmacother 1986; 3: 95–9

    PubMed  CAS  Google Scholar 

  24. Slevin ML, Joel SP, Whomsley R. The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother Pharmacol 1989; 24: 329–31

    Article  PubMed  CAS  Google Scholar 

  25. Harvey VJ, Slevin ML, Joel SP, et al. The effect of dose on the bioavailability of oral etoposide. Cancer Chemother Pharmacol 1986; 16: 178–81

    Article  PubMed  CAS  Google Scholar 

  26. Beijnen JH, Holthuis JJM, Kerkdijk HG, et al. Degradation kinetics of etoposide in aqueous solution. Int J Pharm 1988; 41: 169–78

    Article  CAS  Google Scholar 

  27. Shah JC, Chen JR, Chow D. Preformulation study of etoposide: identification of physicochemical characteristics responsible for the low and erratic oral bioavailability of etoposide. Pharm Res 1989; 6: 408–12

    Article  PubMed  CAS  Google Scholar 

  28. Minami H, Shimokata K, Saka H, et al. Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer. J Clin Oncol 1993; 11: 1602–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Slotervaart Hospital/Netherlands Cancer Institute, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands

    J. D. Jonkman-de Vries, H. Rosing & J. H. Beijnen

  2. Department of Medical Oncology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands

    O. van Tellingen, A. C. Dubbelman, W. W. ten Bokkel-Huinink, B. G. Taal & J. H. Beijnen

  3. Department of Clinical Pharmacy, Medisch Spectrum Twente, Enschede, The Netherlands

    C. Neef

  4. Department of Pharmaceutical Analysis, Faculty of Pharmacy, Utrecht University, Utrecht, The Netherlands

    A. Bult & J. H. Beijnen

Authors
  1. J. D. Jonkman-de Vries
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Rosing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O. van Tellingen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Neef
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. C. Dubbelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Bult
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. W. W. ten Bokkel-Huinink
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. G. Taal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J. H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jonkman-de Vries, J.D., Rosing, H., van Tellingen, O. et al. Pharmacokinetics of Etoposide after Oral and Intravenous Administration in Patients with Gastric Carcinoma. Clin. Drug Invest. 10, 86–95 (1995). https://doi.org/10.2165/00044011-199510020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199510020-00003

Keywords

Search

Navigation